Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib

References

• American Cancer Society. Cancer Facts and Figures 2006. Atlanta, GA: American Cancer Society; 2006.
   Google Scholar
• Muss HB. The role of biological response modifiers in metastatic renal cell carcinoma. Semin Oncol 1988; 15: 30–4
   PubMedGoogle Scholar
• Fisher RI, Coltman CA, Jr, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med 1988; 108: 518–23
   PubMed Web of Science ®Google Scholar
• Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992; 10: 275–81
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271: 907–13
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16–24
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Szcylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125–34
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427–34
   PubMed Web of Science ®Google Scholar
• Heinzer H, Mir TS, Huland E, Huland H. Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. J Clin Oncol 1999; 17: 3612–20
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 2972–80
   PubMed Web of Science ®Google Scholar
• Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, et al. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: Results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 2006; 107: 2254–61
   PubMed Web of Science ®Google Scholar
• Dhanda R, Gondek K, Song J, Cella D, Bukowski RM, Escudier B. A comparison of quality of life and symptoms in kidney cancer patients receiving sorafenib versus placebo. J Clin Oncol 2006; 24: 4534
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115–24
   PubMed Web of Science ®Google Scholar
• Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: A phase II study. Lancet Oncol 2007; 8: 975–84
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–76
   PubMed Web of Science ®Google Scholar
• Atzpodien J, Kuchler T, Wandert T, Reitz M. Rapid deterioration in quality of life during interleukin-2- and alpha-interferon-based home therapy of renal cell carcinoma is associated with a good outcome. Br J Cancer 2003; 89: 50–4
   PubMed Web of Science ®Google Scholar
• Kroger MJ, Menzel T, Gschwend JE, Bergmann L. Life quality of patients with metastatic renal cell carcinoma and chemo-immunotherapy – a pilot study. Anticancer Res 1999; 19: 1553–5
   PubMedGoogle Scholar
• Donnelly S, Walsh D, Rybicki L. The symptoms of advanced cancer: Identification of clinical and research priorities by assessment of prevalence and severity. J Palliat Care 1995; 11: 27–32
   PubMed Web of Science ®Google Scholar
• Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S. Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. J Clin Oncol 1995; 13: 1249–54
   PubMed Web of Science ®Google Scholar
• Kaasa S, Bjordal K, Aaronson N, Moum T, Wist E, Hagen S, et al. The EORTC core quality of life questionnaire (QLQ-C30): Validity and reliability when analysed with patients treated with palliative radiotherapy. Eur J Cancer 1995; 31A: 2260–3
   PubMed Web of Science ®Google Scholar
• Fayers P, Aaronson N, Bjordal K, Sullivan M. EORTC QLQ-C30 Scoring Manual. Quality of Life Unit, EORTC Data Centre, BrusselsBelgium 1995
   Google Scholar
• Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. John Wiley & Sons, Inc, Hoboken, NJ 2004
   Google Scholar
• Fairclough DL. Patient reported outcomes as endpoints in medical research. Stat Methods Med Res 2004; 12: 115–38
   Google Scholar
• King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 1996; 5: 555–67
   PubMed Web of Science ®Google Scholar
• Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139–44
   PubMed Web of Science ®Google Scholar
• Hedeker D, Gibbons RD. Application of random-effects pattern-mixture models for missing data in longitudinal studies. Psychol Methods 1997; 2: 64–78
   Web of Science ®Google Scholar